"Effects of Combined Intron-A/Ribavirin Therapy on Previously Untreated Chronic Hepatitis C Patients."

According to an abstract submitted by the authors to the 28th Annual Meeting of the American College of Clinical Pharmacology, held September 16-18, 1999, in Rockville, Maryland, "This report provides outcome data for a study of the effect of combined Intron-A/Ribavirin therapy for chronic hepatitis C on a group of subjects previously untreated for this condition. Baseline values for this group were reported Last year. All patients had biochemical and histological evidence of chronic hepatitis and were PCR-positive for HCVRNA in serum. The principal findings are as follows: After 24 weeks of treatment, 9 of 21 subjects showed no detectable trace of serum HCVRNA, and an additional 3...

Want to see the full article?

• Purchase this article for only $3.00